Bristol Myers Squibb Company (BMY) vs Gilead Sciences, Inc. (GILD)
Bristol Myers Squibb Company and Gilead Sciences, Inc. are both Drug Manufacturers General companies. Gilead Sciences, Inc. is the larger, with a market value of $183.2B against $125.9B — 1.5× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Bristol Myers Squibb Company trades at 13.8×. Gilead Sciences, Inc. grew revenue faster over the last twelve months: 5.52% against 3.11%. Bristol Myers Squibb Company has the higher net margin (18.9% vs −10.6%) and the higher return on invested capital (13.7% vs −4.48%). Both pay a dividend; Bristol Myers Squibb Company yields more (5.04% vs 4.27%). Across the 22 metrics below, Bristol Myers Squibb Company leads on 15 and Gilead Sciences, Inc. on 7.
Valuation
Profitability
| Metric | BMY | GILD | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 70.16% | 79.59% | 72.77% |
| Operating margin | 24.22% | (8.20%) | 18.90% |
| Net margin | 18.87% | (10.64%) | 8.27% |
| Free cash flow margin | 23.26% | 42.50% | 17.25% |
| Return on equity | 46.63% | (20.68%) | 6.97% |
| Return on assets | 10.18% | (6.17%) | 2.76% |
| Return on invested capital | 13.69% | (4.48%) | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack